Nusano, Primo ink multi-isotope supply deal for cancer drug development

Nusano and Taiwan-based Primo Biotechnology have signed a multi-isotope supply agreement to support Primo’s radiotheranostic pipeline and improve access to key medical isotopes. The deal gives Primo access to five radioisotopes used in targeted cancer therapy development, including lutetium-177 and actinium-225.

Why it matters: - The agreement is designed to help Primo Biotechnology secure the radioisotope supply needed to advance radiotheranostic medicines and targeted cancer therapies. - Access to a more reliable isotope pipeline can reduce a major bottleneck in moving radiopharmaceutical programs from research into clinical use. - The deal also expands commercial demand for Nusano’s production platform as isotope shortages continue to challenge the field.

What happened: - Nusano and Taiwan-based Primo Biotechnology announced a multi-isotope supply agreement. - The partnership supports Primo’s radiotheranostic product pipeline. - Primo will gain access to Nusano-produced radioisotopes, including lutetium-177, actinium-225, indium-111, zirconium-89 and terbium-161.

The details: - Primo Biotechnology is a radiopharmaceutical developer focused on next-generation radiotheranostic drugs. - Dr. Ya-Yao Huang, Primo’s chairman and CEO, said the agreement strengthens the company’s ability to develop and deliver next-generation radiotherapeutics with greater confidence. - Nusano’s production platform combines established technologies from universities and research centers with the company’s patented particle acceleration technology. - Nusano says the platform is one of the first significant advancements in radioisotope production in decades. - The company says the system is smaller and more efficient than traditional setups. - Nusano says the platform can simultaneously manufacture up to 12 different radioisotopes. - Howard Lewin, Nusano co-founder and chief product development officer, said radiotherapeutic developers need dependable access to radioisotopes to move programs from discovery to clinical impact. - Lewin said Nusano’s platform is built to provide reliability and flexibility as customer needs change.

Between the lines: - The agreement signals growing interest in securing nontraditional and scalable isotope supply chains for precision oncology. - For Primo, the deal reduces dependence on a single source of a critical input that can affect timelines, manufacturing and clinical development. - For Nusano, the partnership is a validation point for a technology built around multi-isotope output and supply chain resilience.

What's next: - Primo is expected to use the isotope access to advance its radiotheranostic pipeline. - Nusano will continue positioning its platform as a commercial supplier for developers that need multiple medical isotopes. - The companies did not disclose financial terms or the duration of the agreement.

The bottom line: - The deal ties a radiopharmaceutical developer to a new isotope supplier as both companies bet on rising demand for targeted cancer therapies.